Literature DB >> 16266123

Mycophenolic acid inhibits syncytium formation accompanied by reduction of gp120 expression.

Hideaki Ui1, Satoshi Asanuma, Harumi Chiba, Atsushi Takahashi, Yuichi Yamaguchi, Rokuro Masuma, Satoshi Omura, Haruo Tanaka.   

Abstract

Mycophenolic acid (MPA) was identified as an inhibitor of syncytium formation during the screening of human immunodeficiency virus (HIV) entry inhibitors. MPA is a well-known inhibitor of inosine monophosphate dehydrogenase and anti-HIV activity has been reported in vitro and in vivo. MPA inhibited syncytium formation in T cell-tropic and macrophage-tropic systems with IC50 values of 0.1 and 0.5 microM, respectively. The reduction of HIV gp120 expression by MPA (1.0 microM) was observed by use of Western blot analysis. Furthermore, the addition of guanosine restored both syncytium formation and gp120 expression in the presence of MPA. These results suggest that MPA inhibits not only reverse transcription by depletion of a substrate, GTP, as has been reported, but also syncytium formation through a predominant reduction in the amount of gp120 that is vigorously expressed in the above transformed cells and may be in HIV-infected cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16266123     DOI: 10.1038/ja.2005.69

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  3 in total

Review 1.  Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity.

Authors:  M L Ritter; L Pirofski
Journal:  Transpl Infect Dis       Date:  2009-05-26       Impact factor: 2.228

2.  Penicacids H-J, three new mycophenolic acid derivatives from the marine-derived fungus Rhizopus oryzae.

Authors:  Amine Dilara Pilevneli; Sherif S Ebada; Banu Kaşkatepe; Belma Konuklugil
Journal:  RSC Adv       Date:  2021-11-01       Impact factor: 3.361

Review 3.  Investigational drugs with dual activity against HBV and HIV (Review).

Authors:  Shiyu Sun; Qing Yang; Yunjian Sheng; Yi Fu; Changfeng Sun; Cunliang Deng
Journal:  Exp Ther Med       Date:  2020-11-11       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.